Abstract

BackgroundUnderstanding the physical activity experiences of patients with multiple myeloma (MM) is essential to inform the development of evidence-based interventions and to quantify the benefits of physical activity. The aim of this study was to gain an in-depth understanding of the physical activity experiences and perceived benefits and barriers to physical activity for patients with MM.MethodsThis was a qualitative study that used a grounded theory approach. Semi-structured interviews were conducted in Victoria, Australia by telephone from December 2011-February 2012 with patients who had been treated for MM within the preceding 2–12 months. Interviews were transcribed and analysed using the constant comparison coding method to reduce the data to themes. Gender differences and differences between treatment groups were explored.ResultsTwenty-four interviews were completed. The sample comprised 13 females (54%), with a mean age of 62 years (SD = 8.8). Sixteen (67%) participants had received an autologous stem cell transplant (ASCT). All participants currently engaged in a range of light to moderate intensity physical activity; walking and gardening were the most common activities. Recovery from the symptoms of MM and side effects of therapy, psychological benefits, social factors and enjoyment were important benefits of physical activity. Barriers to physical activity predominately related to the symptoms of MM and side effects of therapy, including pain, fatigue, and fear of infection. Low self- motivation was also a barrier. Women participated in a more diverse range of physical activities than men and there were gender differences in preferred type of physical activity. Women were more likely to report psychological and social benefits; whereas men reported physical activity as a way to keep busy and self-motivation was a barrier. Patients treated with an ASCT more often reported affective benefits of participation in physical activity and fatigue as a barrier. Patients treated with other therapies (e.g., chemotherapy, radiotherapy) were more likely to report pain as a barrier.ConclusionsPatients with MM experience debilitating effects of their condition and therapy, which influences their level and intensity of physical activity participation. Physical activity programs should be individualised; take into consideration gender differences and the impact of different types of therapy on physical activity; and focus on meeting the psychological, coping and recovery needs of patients.

Highlights

  • Understanding the physical activity experiences of patients with multiple myeloma (MM) is essential to inform the development of evidence-based interventions and to quantify the benefits of physical activity

  • We found that participating in light to moderate intensity physical activity is likely to be the most feasible for patients with MM who experience a range of physical limitations that effect mobility, and who are at increased risk of bone fractures and infections [6,7]

  • These findings suggest that patients with MM may find it difficult to meet the American College of Sports Medicine guidelines for cancer survivors, which advise that cancer survivors avoid inactivity and follow the age-appropriate guidelines for aerobic activity; the accumulation of 150 minutes per week of moderate to vigorous intensity physical activity

Read more

Summary

Introduction

Understanding the physical activity experiences of patients with multiple myeloma (MM) is essential to inform the development of evidence-based interventions and to quantify the benefits of physical activity. In Australia, guidelines recommend that autologous stem cell transplantation (ASCT) should be the standard of care in patients up to 65–70 years following induction therapy. This therapy comprises an induction regimen incorporating novel agents (thalidomide, bortezomibor or lenalidomide) designed to preserve the capacity to harvest haematopoietic stem cells. Patients older than 65 years with poor performance status, or younger patients with comorbidities are not eligible for ASCT due to increasing toxicity, regimens usually combine melphalan and steroids with novel agents. Supportive therapy may include the use of bisphosphonates and erythropoietin as per updated guidelines [3]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.